Need a specific person's email?
Browse CureVac's employee directory (about 661 employees) and reveal verified emails free.
CureVac's most common email format is First.Last@curevac.com (ex. John.Doe@curevac.com), used for 96% of curevac.com addresses. CureVac uses 3 email patterns.
| Format | Example | Share of curevac.com |
|---|---|---|
| First.Last@curevac.comMost common | John.Doe@curevac.com | |
| First.MiddleLast@curevac.com | John.MichaelDoe@curevac.com | |
| LF@curevac.com | DJ@curevac.com |
Browse CureVac's employee directory (about 661 employees) and reveal verified emails free.
Biotechnology ResearchBaden-Württemberg, Germany501-1000 Employees
CureVac is a multinational biotechnology company focused on messenger RNA (mRNA) technology for human medicine. It has developed and refined foundational approaches that supported the production of mRNA vaccines used to address COVID-19 and is pursuing additional therapeutic applications of mRNA in areas with high medical need. The company is pursuing both off-the-shelf and personalized cancer vaccine candidates, as well as prophylactic vaccines and approaches that prompt the body to generate therapeutic proteins, aided by omics and computational tools. Headquartered in Tübingen, Baden-Württemberg, CureVac operates sites in the Netherlands, Belgium, Switzerland, and the United States. Founded in 2000, it belongs to the biotechnology research sector and maintains an international footprint through its multiple sites. In 2026, CureVac filed a patent-infringement lawsuit against Moderna in Delaware federal court over mRNA vaccine technology.
Most common format
First.Last@curevac.com
Example: John.Doe@curevac.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.